Is the US seeing a turning point in obesity rates?

The United States has been battling an obesity epidemic since the late 1970s, but there are signs that the steadily rising rates may be starting to decline. Benjamin Rader, an epidemiologist at Boston Children's Hospital and Harvard Medical School, said he believes a turning point could be approaching. In 2024, Rader and his team published a study based on data from more than 16 million adults, showing a decline in obesity prevalence in 2023 for the first time in over ten years.

The National Health and Nutrition Examination Survey also indicated a slight drop between 2021 and 2023. Recent surveys have also provided evidence of decreasing figures. Amid this promising trend are new weight-loss drugs like Ozempic, Wegovy, and Zepbound, which have gained popularity and prescriptions have quadrupled in recent years.

These drugs, originally developed to treat Type 2 diabetes, help people lose weight by promoting feelings of fullness and slowing gastric emptying. While Rader and others speculate that these medications have contributed to the weight loss, there is no definitive proof of a causal relationship. Some researchers predict that obesity rates will continue to rise through 2035, but epidemiologists caution that these models may not fully account for the impact of GLP-1 drugs.

So far, only a small percentage of obese people use these drugs, and many stop treatment within a year. More extensive data is needed to determine if the drugs will have a lasting effect on obesity rates. Regardless of whether obesity rates are declining, Rader emphasizes that obesity remains a significant public health crisis in America and requires attention, funding, and alternative solutions, particularly as GLP-1 medications may not be accessible to all Americans due to price and other factors.